The question of whether to start with a standard GLP-1 dose or a microdosing protocol doesn't have a single right answer. It has a right answer for you, based on your health history, goals, tolerance, and what you're willing to manage during treatment.

This article lays out the differences honestly, with reference to what the clinical literature supports, so you can go into a conversation with your physician with a clear picture of the tradeoffs.

"Microdosing" in the GLP-1 context refers to using doses meaningfully lower than standard therapeutic targets, often a fraction of the recommended maintenance dose, on a schedule intended to produce continuous low-level receptor stimulation rather than the peaks that come with weekly high-dose injections.

Standard dosing follows titration protocols like those used in the STEP and SURMOUNT clinical trials, starting at a low dose and escalating to a therapeutic target over weeks to months. For semaglutide, the maintenance dose in obesity trials was 2.4mg weekly. For tirzepatide, it was 5mg to 15mg weekly.

Microdosing doesn't have a universally agreed-upon definition. In clinical practice, it typically means doses meaningfully lower than the standard therapeutic target, sometimes given on a modified schedule, based on individual physician judgment. The goal is meaningful receptor activation without the sharp peaks that tend to drive side effects.

No large-scale randomized trials have been specifically designed to test a formal microdosing protocol. The evidence base for lower doses draws primarily from dose-response data in larger trials and observational clinical experience.

The STEP trial data shows that patients at lower dose levels of semaglutide still achieved clinically meaningful weight loss. A 2020 dose-finding study published in The Lancet Diabetes & Endocrinology found that semaglutide at doses as low as 0.4mg produced meaningful appetite reduction and weight loss compared to placebo, though less than higher doses.

The dose-response curve for GLP-1 medications is not perfectly linear. At very low doses, you get meaningful appetite effects. As doses increase, you get more weight loss, but also more GI side effects. At some point, the additional benefit of dose increases shrinks relative to the additional burden of side effects, though this threshold varies considerably between individuals.

Standard dosing is supported by more robust clinical evidence. The major trials were designed around standard protocols, and the efficacy numbers that GLP-1 medications are celebrated for, 15% to 21% average weight loss over 68 to 72 weeks, come from standard dose arms.

If you're in good GI health, haven't had problems with medications before, and have a substantial weight loss goal, the standard titration approach gets you to the therapeutic target faster and produces more total weight loss over a given time period.

Adherence is also somewhat simpler with a standard once-weekly injection. A fixed protocol is easier to maintain than a more complex multi-day dosing schedule.

Microdosing appeals primarily to patients who have had or anticipate having significant problems with standard dose side effects, particularly GI symptoms.

For patients who started standard GLP-1 therapy and found nausea or vomiting intolerable at dose escalation points, a sustained low dose can allow them to stay on therapy and make progress, even if more slowly. A five percent weight loss achieved on a protocol you maintain is meaningfully better than a potential fifteen percent loss from a protocol you stop after six weeks.

There's also an argument for microdosing as a first-line approach for GI-sensitive patients, rather than trying and failing standard dosing. Starting at a very low dose and staying there, or escalating far more slowly than standard protocols, may prevent the early dropout that's common with GLP-1 therapy.

The microdose semaglutide benefits include better tolerability, lower risk of severe nausea or vomiting, and in some cases better overall adherence. What it trades is a slower path to results and likely a lower ceiling on total weight loss at equivalent treatment duration.

Before talking to your physician, it helps to be honest with yourself about a few things:

How sensitive is your GI system generally? If you've had significant nausea with other medications, antibiotics, iron supplements, or anything else, you're more likely to be sensitive to GLP-1 side effects and may be a better candidate for a microdosing start.

How much weight do you want to lose, and over what timeframe? If you have a modest goal (five to ten percent of body weight) and you're patient about timeline, microdosing is a very reasonable path. If you're aiming for significant weight reduction and want to maximize speed, standard dosing gets you further faster.

What's your history with GLP-1 therapy? If you've already tried a standard protocol and had a difficult experience, microdosing gives you a way back to GLP-1 therapy at a level your system can handle.

How important is simplicity versus optimization? Microdosing protocols can involve more complex dosing schedules. If a simple weekly injection is easier for you to maintain, that has real adherence value.

EllieMD's microdose program is designed specifically for patients who want a more gradual, closely monitored approach. Your physician will help you think through which protocol is right for your situation during consultation.


Individual results may vary. All prescriptions require approval by a licensed medical provider. Compounded medications are not FDA-approved. EllieMD facilitates access to independent healthcare providers and pharmacies and does not provide medical care or dispense medications.